Mark Penney
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Glioma Diagnosis and Treatment, Chronic Obstructive Pulmonary Disease (COPD) Research, Computational Drug Discovery Methods, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Prevalence of lymphoreticular prion protein accumulation in UK tissue samples(2004)441 cited
- → Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study(2017)274 cited
- → Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction(2023)96 cited
- → A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease(2017)91 cited
- → Structural and functional characterization of a specific antidote for ticagrelor(2015)88 cited
- → Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities(2019)87 cited
- → Expression of hypoxia‐inducible factor 1α in tumours of patients with glioblastoma(2002)85 cited
- → Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape(2018)74 cited
- → Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt–Jakob disease(2004)74 cited
- → Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network(2019)57 cited